ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase A, participants will get unique doses and schedules of oral ABBV-744 tablet to determine safe dosing program. Added individuals will probably be enrolled for the recognized monotherapy dosign program. In Section B, contributors will get oral ruxolitinib and ABBV-744 will likely be offered as "increase-on" therapy. In Section C, individuals